Search results for " Bisphosphonates"
showing 10 items of 32 documents
Amorphous, Smart, and Bioinspired Polyphosphate Nano/Microparticles: A Biomaterial for Regeneration and Repair of Osteo-Articular Impairments In-Situ
2018
Using femur explants from mice as an in vitro model, we investigated the effect of the physiological polymer, inorganic polyphosphate (polyP), on differentiation of the cells of the bone marrow in their natural microenvironment into the osteogenic and chondrogenic lineages. In the form of amorphous Ca-polyP nano/microparticles, polyP retains its function to act as both an intra- and extracellular metabolic fuel and a stimulus eliciting morphogenetic signals. The method for synthesis of the nano/microparticles with the polyanionic polyP also allowed the fabrication of hybrid particles with the bisphosphonate zoledronic acid, a drug used in therapy of bone metastases in cancer patients. The r…
Osteonecrosis of the jaw after long-term oral bisphosphonates, followed by short-term denosumab treatment for osteoporosis: a case report
2014
Bisphosphonates and denosumab are antiresoptive agents and are mainly used for management of metastatic bone cancer, osteoporosis and other diseases. Bisphosphonates (BP) can reduce skeletal related events (SRE) by 30–50%1; denosumab (D) has been found even more effective than BP2. BP and D have been both associated to osteonecrosis of the jaw (ONJ). We report a case of an osteoporotic woman (62 yrs), complaining maxillary intense pain after a recent tooth molar extraction, observed in July 2013 at our centre. She mentioned previous treatments with monthly ibandronate (Bonviva ® 150 mg) per os (from January 2003 to April 2010), risedronate (35 mg weekly, from May 2010 to May 2012) and two a…
Description of a new protocol with application of PRP in post-extraction sockets of a patient treated with aminobisphosphonate
2014
Background. Platelet-rich plasma (PRP), an autologous product rich of growth factors, is an adjunctive bio-material able to promote healing in dental surgery, especially in elderly. It is also used for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ) and for application in post-extraction alveolar site in order to obtain mucosa healing and reduce BRONJ risk. Aim. To describe a dental extraction PRP enriched protocol adopted in a patient treated with aminobisphosphonate in order to evaluate the healing of the post-extraction alveolar site. Case report. An osteoporotic woman (71 yrs), treated with alendronate per os for 10 years and suspended from 1 year, currently with vitami…
Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
2008
BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic …
Novel formulations of oral bisphosphonates in the treatment of osteoporosis
2022
AbstractOral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still mainta…
A SIMPLE SURGICAL-MEDICAL PROTOCOL TO CARRY OUT DENTAL EXTRACTIONS IN PATIENTS IN THERAPY WITH BISPHOSPHONATES: OUR EXPERIENCE
2014
Aim. Bisphosphonate Related OsteoNecrosis of the Jaw (BRONJ) is described as an adverse event related to amino-bisphosphonate (NBP) therapy, occurring as a result of reduced bone resorption and bone turnover. One of the most significant risk factor associated with the onset of BRONJ is tooth extraction even if not yet supported by definitive scientific evidences. The aim of this study is to propose a simple surgical/medical protocol to carry out dental extractions in patients in therapy with NBPs in order to minimize the BRONJ risk. Materials and methods. Eighty-eight patients currently or previously treated with NBPs were selected for extractions of compromised teeth. Patients were divided…
Herbicidal derivatives of aminomethylenebisphosphonic acid. Part III. Structure-activity relationship.
1997
Derivatives of aminomethylenebisphosphonic acids constitute a class of promising herbicides. More than 40 N-substituted aminomethylenephosphonic acids were synthesized and evaluated for their herbicidal activity on common cress (Lepidium sativum L.) and cucumber (Cucumis sativus L.). Some of the tested compounds were found to exhibit strong herbicidal properties being equal in activity with the popular herbicide glyphosate as well as parent N-pyridylaminomethylenephosphonic acids. N-Substituted iminodi(methylenephosphonic) acids, which may be considered as close analog of glyphosate, were inactive toward test plants.
IMAGING FINDINGS SYSTEMATIZATION AND IMAGING STAGING PROPOSAL IN BISPHOSPHONATES ASSOCIATED OSTEOMYLITIS/OSTEONECROSIS OF THE JAWS
2011
INTRODUZIONE I Bifosfonati (BPs), farmaci analoghi al pirofosfato, sono usati nel trattamento dell’osteoporosi, nella malattia di Paget, nel mieloma multiplo e nelle metastasi ossee. Sebbene siano molto utili nella sintomatologia osteolitica, dal 2003 è stata descritta la correlazione tra la loro somministrazione e l’insorgenza dell’osteonecrosi dei mascellari (BRONJ). Il nostro studio si propone di descrivere la superiorità delle immagini TC nei pazienti in cura con BPs affetti da BRONJ, e di raggruppare gli stessi in accordo con una classificazione radiologica basata sulla presenza o meno dei segni dell’osteomielite/osteonecrosi e delle successive complicanze. Si dimostra, inoltre, l’impo…
Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study
2019
The patients’ persistence with osteoporosis treatments is low. This retrospective, multicenter survey showed that almost 30% of osteoporotic patients discontinued the treatment within the first 6 months and that those taking drinkable bisphosphonates were less likely to interrupt the therapy; instead, the use of generic bisphosphonates was associated to a more precocious interruption. Purpose: Low persistence with osteoporosis medications is associated with higher fracture risk. This study aimed to assess the persistence to treatment with oral bisphosphonates among Italian osteoporotic patients under treatment for at least 6 months and to evaluate whether the different oral formulations of …
Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed
2014
AbstractRecent data suggest that the traditional definition of bisphosphonate-associated osteonecrosis of the jaw (ONJ) may exclude patients who present with the non-exposed variant of the condition. To test the hypothesis that a proportion of patients with ONJ remain undiagnosed because their symptoms do not conform to the traditional case definition, we did a secondary analysis of data from MISSION (Multicentre study on phenotype, definition and classification of osteonecrosis of the jaws associated with bisphosphonates), a cross-sectional study of a large population of patients with bisphosphonate-associated ONJ who were recruited in 13 European centres. Patients with exposed and non-exp…